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Since the advent of highly active antiretroviral therapy in 1996, we have seen dramatic
changes  in morbi-mortality rates from human immunodeﬁciency virus-positive patients. If
on the one hand, the immunologic preservation-associated with the use of current antiretro-
viral  therapy markedly diminishes the incidence of opportunistic infections, on the other
hand  it extended life expectancy of human immunodeﬁciency virus-infected individuals
similarly  to the general population. However, the management of critically ill human immu-
nodeﬁciency  virus-infected patients remains challenging and troublesome for practicing
clinician.  Sepsis – a complex systemic inﬂammatory syndrome in response to infection –
is  the second leading cause of intensive care unit admission in both human immunode-
ﬁciency  virus-infected and uninfected populations. Recent data have emerged describing
a  substantial burden of sepsis in the infected population, in addition, to a much poorer
prognosis  in this group. Many factors contribute to this outcome, including speciﬁc etiolo-
gies,  patterns of inﬂammation, underlying immune dysregulation related to chronic human
immunodeﬁciency  virus infection and delays in prompt diagnosis and treatment. This brief
review  explores the impact of sepsis in the context of human immunodeﬁciency virusinfection,  and proposes future directions for better management and prevention of human
immunodeﬁciency  virus-associated sepsis.
uals have shifted from the traditional AIDS-related illnesses
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lthough access to highly active antiretroviral therapy
1,2HAART) has prolonged survival and improved life quality,
uman immunodeﬁciency virus (HIV)-infected patients with
evere  immunosuppression or comorbidities may  develop
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care  unit (ICU).
Causes  of admissions to ICU in HIV-infected individ-40-360, Brazil.
to  non-AIDS-related diagnoses. Nevertheless, opportunistic
infections still represent 30%–40% of admissions in developing
settings.3
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Data generated from several hospital cohorts had demon-
strated  that respiratory failure, followed by sepsis, and
neurological diseases are the main causes of ICU admis-
sion  among HIV-infected individuals.4–7 Respiratory failure
accounts for more  than 20% of all ICU admissions. Interest-
ingly,  in ART-treated individuals, the etiologies of respiratory
failure  are similar to those seen in general critically ill popu-
lation  (i.e. Streptococcus pneumoniae, sepsis, chronic obstructive
pulmonary disease, and asthma).8,9
Sepsis accounts for 15%–30% of all ICU admissions of
HIV-infected individuals.6.8,10,11 Nevertheless, HIV-infected
patients with severe sepsis are less often admitted to ICU, even
when  compared to patients with similar clinical conditions or
higher expected lethality.12 Studies undertaken in the current
HAART  era identiﬁed sepsis as an increasing cause of admis-
sion  to ICU.8,10 Longer life span, more  exposures to invasive
procedures and higher organ dysfunction index at admission
may  partially explain this phenomenon.
The typical immunologic abnormalities associated with
chronic  HIV disease may  predispose such individuals to sys-
temic  bacterial infections.13,14 Therefore, it has been proposed
that  sepsis may  present with distinctive clinical, inﬂamma-
tory,  and prognostic features in this especial population.
HIV-associated  sepsis
Clinical  presentation
The main microbiology focus of infection mirrors those usu-
ally  seen in uninfected individuals. Lung is the most common
site  of infection ranging from 52% to 72%.15–17 In two studies,
the  etiologies were  primarily nosocomial ﬂora: Gram-negative
rods,  such as Pseudomonas aeruginosa and Acinetobacter sps.;
Gram-positive cocci, and fungi, especially, Candida sps.17,18
In contrast, others had found a predominance of fungal and
mycobacterial infections in HIV-associated sepsis. The fungi
identiﬁed  were  Pneumocystis jirovecii, Histoplasma capsulatum,
Cryptococcus sp and Candida albicans.16 Of note, Haddy et al.19
reported more  than 10% incidence rate of polymicrobial infec-
tions  in HIV-related septicemia. Taken together, the data
suggest  that a wide empirical antimicrobial coverage is warr-
anted  in HIV septic patients. Further, the absence of classical
clinical  signs of sepsis in HIV-infected patients is a remark-
able  differential feature. Fever was  absent in more  than 45%.
Pneumocystis  jirovecy pneumonia (PCP) is the single most com-
mon  AIDS-related infection, which contributes as a source of
sepsis.15,16,18
HIV septic patients tend to spend more  time in the ICU, are
more  severely ill (i.e. higher SAPS II, APACHE II, SOFA scores),
most  likely come from wards  and needed invasive support and
antibiotics  more  often. Although those characteristics may
predispose  infected individuals to acquisition of multidrug-
resistant organisms, only catheter-related bacteremia has a
higher incidence in the HIV-infected population admitted to
ICU compared to controls.20Inﬂammatory  features
Advanced immunosuppression-associated with untreated
HIV  disease may  blunt the systemic host response to 0 1 5;1  9(1):77–81
infection; as a result, the levels of inﬂammatory biomarkers
and  the pathognomonic signs of infection might be profoundly
depressed or even absent.21 Silva et al.16 showed that at admis-
sion  septic HIV-infected patients presented with lower white
blood  counts, C-reactive protein (CRP), and Procalcitonin (PCT).
In  contrast, initial serum concentrations of IL-10 – a marker
of  immune dysfunction – were signiﬁcantly higher in HIV-
infected  septic patients than in uninfected patients [4.4 pg/mL
(1.0–38.1)  vs. 1.0 pg/mL (1.0–2.7), respectively (p = 0.005)]. In
addition,  Amancio et al.22 showed that serum IL-6 levels
were  signiﬁcantly associated with mortality of HIV-infected
patients with septic shock in a comparable fashion as seen
in  uninfected individuals. Interestingly, a tendency for persis-
tently  high levels of CRP and PCT was  noted in non-survivors
HIV septic patients. Therefore, serial monitoring of these acute
phase  reactants could probably identify those who  would ben-
eﬁt most from intensive care support.
Prognosis
There is a robust high-quality data demonstrating a detrimen-
tal  impact, both short-term and long-term, of HIV infection on
sepsis (Table 1). It is estimated that in-ICU mortality rate of
HIV-associated sepsis range from 29% to 76%. Similarly, those
rates  persist after six months of patient follow-up. Recently,
Akgun23 showed that HIV-infected patients were  more  often
admitted  to ICU, particularly for respiratory and sepsis related
diagnoses,  and experienced higher 30-day mortality compared
with  uninfected patients. The detrimental impact of sepsis
could  not be solely attributed to immunological failure associ-
ated  with HIV infection per se, because in the latter study more
than  50% of infected subjects had viral suppression and mean
CD4+  count were  281 cells/mm3. It is speculated that residual
immune  dysregulation syndrome may  play a crucial role in
explaining  this poor outcome, even in controlled HIV-infected
patients with sepsis.26
Further, Mrus et al.12 showed that in a cohort of severe sep-
tic  patients, those with HIV/AIDS had a statistically signiﬁcant
higher  risk of mortality compared with uninfected severe sep-
tic patients (29% vs. 20%; p < 0.0001). This risk persists after
adjustments for potential confounders that could inﬂuence
the  outcome.
Few studies have evaluated the impact of sepsis in HIV-
infected patients with suppressed viremia. Cobos-Trigueros
et al.20 showed that sepsis was  a predictor of in-ICU mortal-
ity,  independently of HIV serological status, therefore, not just
limited  to the HIV-infected population. This ﬁnding is still dif-
ﬁcult to explain, but it seems reasonable to believe that viral
suppressed  subjects might have the same hospital behavior
patterns  (etiologies, clinical features) found in septic unin-
fected  patients.
Impact  of  antiretroviral  therapy
The introduction of HAART has increased substantially in-
hospital  survival of critically ill HIV-infected patients in
27,28developed  countries ranging from 43% to 80%. In contrast,
in  developing settings those ﬁgures are lower, reﬂecting the
high  rates of late HIV presenters and opportunistic infections
commonly seen in those places.15 Modern ICU standards of
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Table 1 – Studies which HIV-associated sepsis was independently predictor of mortality.
Author [reference] Study year HIV-associated sepsis
prevalence  (%)
Sepsis as admission diagnosis and ICU mortalitya
Akgun K.M. et al. 23 2002–2010 10 Sepsis was a risk factor for 30-day mortality compared
with other admission diagnoses, 26.8 (5.25–137)
Amancio F.F. 24 2006 20 Septic shock independently increase ICU mortality and
24-month mortality, 4.38(1.78–10.76), 3.01(1.31–6.90),
respectively
Chiang H.H. 11 2001–2010 33 Sepsis independently increased hospital mortality, 2.91
(1.11–7.62)
Coquet et al. 25 1996–2005 23 Severe sepsis independently increased ICU mortality,
3.67 (1.53–8.80)
Japiassú A. et al. 18 20 Severe sepsis/septic shock independently increased
28-day mortality, 3.13 (1.21–8.07)b
Croda J. 15 1996–2006 31 Sepsis independently increased ICU mortality, 3.16
(1.65–6.06)
Vargas-Infante Y.A. et al. 3 1985–2006 26 Septic shock independently increased ICU mortality, 2.4
(1.1–5.2)b
Mrus J.M. 12 1999 10 Patients with severe sepsis and HIV/AIDS had increased
mortality, 2.41 (2.23–2.61)
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b Values are given as hazard ratio (95% conﬁdence interval).
are unrelated to HIV therapy (i.e. early-goal therapy,29 prone
osition,30 low-tidal volume,31 intensive insulin therapy32)
ay  explain itself the survival improvement, although studies
esigned  to speciﬁcally assess the effect of those interventions
re  limited.
Whether or not the administration of HAART during ICU
tay  is beneﬁcial remains a matter of continuous debate. Cur-
ently,  randomized clinical trials evaluating this issue have
ot  been performed yet. The data are extrapolated from
tudies  enrolling participants in the non-ICU setting, less crit-
cally  ill and not receiving critical support therapy such as
echanical  ventilation and vasopressors. The generalizabil-
ty  of these results to critically ill HIV-infected patients must
e  done with caution. Furthermore, Huang et al. had already
nderscored the peculiar challenges related to antiretroviral
se  in hemodynamically unstable patients – bioavailability,
rug interactions, immune reconstitution disease, and toxic
ffects.33
The cumulative data show no signiﬁcant effect of HAART
n  short-term survival of critically ill HIV-infected patients,
part  from seven studies that argue against it. Remarkably,
ost of these studies included a substantial proportion of
IV-late  presenters, severely immunosuppressed with AIDS-
elated  diagnosis at ICU admission (Table 2).
HAART use during ICU tended to be associated with
ess  progression to AIDS-related events during the follow-
ng  6-month follow-up period. A more  robust immunologic
ecovery and rapidly declining of viral load during HAART
se  in-ICU may  contribute to this result. In addition, Meybeck
t  al.36 have shown that in-ICU HAART use was  associated
ith higher incidence of antiretroviral drug resistance with
AART  use (25%) compared to 7% among those without
 = 0.02). Dynamic and complexes pharmacokinetics interac-
ions  involving antiretrovirals and common ICU medications,
s  well as erratic gastrointestinal absorption related to critical
llness  may  explain the emergence of drug resistance in the
AART  treated group.e speciﬁed.
In  short, to date, HAART prescription for both, treatment-
naïve or experienced patients cannot be routinely adminis-
tered  for HIV-associated sepsis. Only a sub-group of patients
(i.e.  those with AIDS-related OI) may  beneﬁt from HAART
when  administered soon after admission to ICU. Zolopa et al.37
have shown that in non-critically ill HIV-infected patients,
those  who started HAART within 2-weeks after OI treatment,
had  a lower rate of progress to AIDS or death. As a result,
each  case must be individualized, and possible beneﬁts should
outweigh  the potential risks associated with the antiretroviral
use.38
Treatment  and  prevention
The mainstay of therapy in HIV-associated sepsis should
reﬂect  the exact same priorities highlighted in several clin-
ical  guidelines.39 However, some issues must speciﬁcally be
addressed  in this setting in order to curb the huge burden of
infection  during sepsis. A signiﬁcant proportion of patients
are  still unaware of the HIV diagnosis status at the time of
ICU  admission.15,18 Further, unnoticed AIDS diagnosis is asso-
ciated  with a poorer outcome. Consequently, efforts should
be  added, in order to ensure early HIV diagnosis and HIV-
associated sepsis.
The  fact that no single HIV-related factor (i.e. CD4+ count,
VL)  was shown to be directly associated with mortality dur-
ing  ICU stay could be a strong argument against widespread
HAART use in ICU. Conversely, multiple factors associated
with  organ dysfunction at admission (mechanical ventilation
use,  APACHE II score) best explain the higher burden of sep-
tic  HIV patients. For this reason, optimization of critical care
bundles  might be more  beneﬁcial as compared with HAART
implementation in this special setting.Whether enhanced vaccine programs  for prevention of
respiratory  pathogens, improved engagement of care, broader
use  of HAART, and enhanced nosocomial-infection pre-
vention  protocols in ICU would improve care, and thus
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Table 2 – Studies in which ART administration during ICU was associated with improved hospital survival.
Author, year, reference N Median CD4+
count
(cells/mm3)
New HIV
diagnosis  (%)a
AIDS-related ICU
admission (%)
Outcome
Morquin D., 2012, 34 98 173.5 ± 192b 8.2 84 Introducing or continuing ARV in ICU was
protective [OR 0.278 (0.082–0.939; p = 0.03930)]
Amancio F.F., 2012, 24 125 116 39 92 Survival to ICU discharge independently
associated  with ART use during ICU stay [OR
0.19 (0.05–0.77)]
Adlakha A., 2011, 27 192 110 19 51 Receipt of ARV was associated with ICU
survival [OR 2.44 (1.01–4.94)]
Croda J., 2009, 15 278 39 38 81 ART use in ICU was negatively predictive of
6-month mortality, especially if introduced
during the ﬁrst 4 days of admission to ICU
[HR 0.50 (0.35–0.71)]
Vargas-Infante Y.A., 2007, 3 90 257 31 88 No prior ARV independently increased ICU
mortality [HR 3.33(1.43–10)
Casalino E., 2004, 10 426 134b 40 22 Long-term mortality was associated with
ARV availability [OR 0.45 (0.25–0.82)]
Morris A., 2003, 35 58 17 27.6 100 ARV use either before or during
hospitalization  was associated with lower
ICU mortality [OR 0.14 (0.02–0.84, p = 0.03)]
 adm
ra HIV diagnosis within 30 days of hospitalization or diagnosis at ICU
b Data provided as mean ± SD.
prevent HIV-associated sepsis are questions to be further
elucidated.
Conclusions
Currently, even with aggressive state of the art intensive care,
HIV-associated sepsis remains a deadly entity, although sub-
stantial  degrees of improvements have occurred over the years
transforming  HIV disease in a chronic condition. In order to
ameliorate  the extreme mortality associated with the condi-
tion,  a future prospective randomized controlled trial needs
to  be designed to deﬁne optimal time to prescribe HAART in
ICU  (immediately vs. deferred approach). In particular, when
to  initiate antiretrovirals during HIV-associated sepsis should
also  be addressed. Whether or not a sub-group of patients
would beneﬁt from HAART introduced in ICU is still an elu-
sive  question. Besides, incorporation of antiretrovirals drug
monitoring  levels in routine ICU standard of care should also
be  investigated, because altered pharmacokinetic, caused by
malabsorption, organ failure and drug interactions could place
infected  patients at risk of developing sub-therapeutic drug
levels,  and subsequently emerging drug resistance.
Finally, the development of bedside biomarkers is an
intriguing evolving strategy, selecting those high-risk individ-
uals  who would be enrolled in future trials for sepsis.
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